MK 7264

Drug Profile

MK 7264

Alternative Names: AF-219; MK-7264; R1646; RG-1646; RO 4926219

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Afferent Pharmaceuticals; Roche
  • Class Analgesics; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
  • Discontinued Overactive bladder; Pain

Most Recent Events

  • 10 Nov 2016 Efficacy data from a phase II trial in Cough presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2016)
  • 01 Nov 2016 Afferent Pharmaceuticals completes a phase II trial for Cough (In adults, In the elderly, Treatment-resistant) in USA (PO) (NCT02612610)
  • 01 Oct 2016 Afferent Pharmaceuticals completes a phase-II clinical trial in Cough (In adults, In the elderly, Treatment-resistant) in United Kingdom (PO) (NCT02476890)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top